Epstein–Barr virus (EBV) is one of the most common human viruses, infecting around 90–95 percent of adults worldwide. In this episode, Florian Krammer explains the biology of EBV, a herpesvirus with a large DNA genome and a complex life cycle that includes both active replication and lifelong latent infection in B cells. The discussion covers how EBV spreads through saliva and close contact, why primary infection in adolescents often leads to infectious mononucleosis, and how the virus can persist silently in the body for decades. EBV is also associated with several cancers, including lymphomas and nasopharyngeal carcinoma, and recent research strongly links EBV infection to the development of multiple sclerosis. The episode explores the evidence behind this connection and why developing an effective EBV vaccine could potentially prevent not only infectious mononucleosis but also some cancers and autoimmune disease.

Epidemiological link between EBV infection and multiple sclerosis: https://www.science.org/doi/10.1126/science.abj8222

Potential mechanistic link between (EBNA1 antibodies) between EBV infection and multiple sclerosis: https://pmc.ncbi.nlm.nih.gov/articles/PMC9382663/

Review about disease caused by EBV and potential vaccines and therapeutics (unfortunately behind a paywall): https://www.nature.com/articles/s41579-025-01181-y

+++++

Support viroLOGICAL on Steady:

Questions, feedback or topic suggestions?

+++++

Krammer laboratory information

Krammer Laboratory at the Icahn School of Medicine at Mount Sinai

Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness

Ignaz Semmelweis Institute

+++++

Conflict of interest statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.

I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).

My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.

My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.

My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.